FDA quickly follows a voluntary pause for CAR-T 2.0 with a clinical hold to investigate 2 patient deaths

Celyad’s voluntary pause didn’t last long.

The biotech put out word after the market closed Monday that the FDA has swiftly followed up the news of 2 patient deaths and an announced pause with a clinical hold, shifting control over the trial halt to federal regulators.